Domov › Ploščatocelični karcinom glave in vratu › Kalifornija › Los Angeles
Klinične študije za Ploščatocelični karcinom glave in vratu v Los Angeles, CA
42 študij za Ploščatocelični karcinom glave in vratu išče udeležence na lokacijah v Los Angeles in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Vključevanje udeležencevFaza 3
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Vključevanje udeležencevFaza 1
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Vključevanje udeležencevFaza 2/3
- Site #0106, Los Angeles
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Vključevanje udeležencevFaza 1
- Research Site, Los Angeles
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Vključevanje udeležencevFaza 3
- Valkyrie Clinical Trials, Los Angeles
- University of California, Los Angeles UCLA, Los Angeles
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Vključevanje udeležencevFaza 2
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Vključevanje udeležencevFaza 2
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- in še 1
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Vključevanje udeležencevFaza 3
- UCLA Hematology Oncology, Los Angeles
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Vključevanje udeležencevFaza 1/2
- University of Southern California, Los Angeles
Intratumoral N17350 in Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Vključevanje udeležencevFaza 2
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Vključevanje udeležencevFaza 1
- Site 105 - START Los Angeles, Los Angeles
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Vključevanje udeležencevOpazovalna študija
- USC/Norris Comprehensive Cancer Center, Los Angeles
- University of California, Los Angeles, Los Angeles
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- START Los Angeles, Los Angeles
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- University of Southern California, Los Angeles
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Vključevanje udeležencevFaza 2
- University of California Los Angeles, Los Angeles
- Samuel Oschin Cancer Center, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
Vključevanje udeležencevFaza 3
- USC / Norris Comprehensive Cancer Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
SMP-3124LP in Adults With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- The Angeles Clinic and Research Institute, Los Angeles
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Vključevanje udeležencevFaza 1/2
- Los Angeles Cancer Network, Los Angeles
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Vključevanje udeležencevFaza 1/2
- California Research Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Ellison Clinic at Saint John's, Los Angeles
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- The Regents of the University of California, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Vključevanje udeležencevFaza 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Vključevanje udeležencevFaza 1
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Vključevanje udeležencevFaza 1
- Start Lacn, Los Angeles
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Vključevanje udeležencevFaza 3
- GSK Investigational Site, Los Angeles
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 2
- USA06-0, Los Angeles
- USA16-0, Los Angeles
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Vključevanje udeležencevFaza 3
- University of California Los Angeles, Los Angeles
A Study of VET3-TGI in Patients With Solid Tumors
Vključevanje udeležencevFaza 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Vključevanje udeležencevFaza 1
- USC - Norris Comprehensive Cancer Center, Los Angeles
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- University of Southern California, Los Angeles
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Research Site 125, Los Angeles
- Research Site 133, Los Angeles
- Research Site 103, Los Angeles
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Vključevanje udeležencevFaza 1/2
- University of Southern California, Los Angeles
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Vključevanje udeležencevFaza 1/2
- UCLA Medical Center, Los Angeles
A Study of NX-1607 in Adults With Advanced Malignancies
Vključevanje udeležencevFaza 1
- University of Southern California, Los Angeles
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Keck School of Medicine of USC, Los Angeles
- UCLA, Los Angeles
Študije za Ploščatocelični karcinom glave in vratu v drugih mestih
- Houston, TX47 študij
- Boston, MA40 študij
- New York City, NY39 študij
- Nashville, TN39 študij
- St. Louis, MO28 študij
- Arlington, VA26 študij
- Philadelphia, PA26 študij
- Chicago, IL26 študij
- Atlanta, GA24 študij
- San Antonio, TX22 študij
- New Haven, CT22 študij
- Pittsburgh, PA22 študij
Druge študije v Los Angeles
- Nemalicelični pljučni rak87 študij
- Rak (vse vrste)74 študij
- Rak dojke73 študij
- Rak prostate61 študij
- Kolorektalni rak59 študij
- Metastatski rak57 študij
- Rak jajčnikov50 študij
- Rak pljuč45 študij
- Rak trebušne slinavke35 študij
- Rak endometrija34 študij
- Melanom34 študij
- Trojno negativni rak dojke27 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.